Pyxis Oncology Inc. Common Stock (PYXS)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Pyxis Oncology and immediately see a clinical-stage biotech, not a predictable business. It has 56 employees and is developing antibody-drug conjugates for solid tumors, but no approved product. The filed figures show fiscal Q2 2026 net loss of $25.3 million and diluted EPS of -$0.40, and fiscal Q1 2026 net loss of $23.3 million and diluted EPS of -$0.37. For FY2025, revenue was $13.9 million, net loss $79.6 million, and diluted EPS -$1.28; FY2024 was similar, with revenue $16.1 million and net loss $77.3 million. Revenue is not growing; it fell from FY2024 to FY2025, and the company lost money in each of the last four years, so the provided Lynch category is none. The cash engine is going the wrong way: trailing free cash flow is -$67.9 million, a -44.0% FCF yield, per FairStock. At the 2026-10-13 close, FairStock shows P/E -1.32, P/B 10.28, ROE -179.10%, ROCE -62.95%, and D/E 1.56. Those are not value markers. The Piotroski F-Score of 1/9 and Altman Z-Score of -11.10 point to financial weakness and distress risk. There may be scientific optionality in PYX-201 and PYX-102, but I cannot underwrite a moat from Phase 1 data. Without earnings, positive cash flow, or a margin of safety in assets, the $1.85 price is speculative. The FairStock Score of 57/100 is not enough to call it a Graham bargain.

In plain English: Pyxis Oncology is a small healthcare company trying to develop new cancer medicines, mostly for solid tumors. It is not yet profitable and loses a lot of money each year, with negative cash flow. At $1.85 on 2026-10-13, the stock does not look cheap based on the numbers shown; it looks more like a risky bet on future trial results than a proven business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer